A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency

Trial Profile

A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors OPKO Health; PROLOR Biotech
  • Most Recent Events

    • 15 Jun 2017 Topline post-hoc analysis results published in OPKO Health media release.
    • 10 Jun 2017 Biomarkers information updated
    • 09 May 2017 According to an Opko health media release, based on the data from this trial the company is preparing a BLA for FDA submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top